CYP19A1 and neoplasm: Additionally, the EBCTCG meta-analysis2 of aromatase inhibitors versus tamoxifen in postmenopausal women found similar proportional reductions in recurrence in HER2-positive and HER2-negative disease so the apparent lack of benefit from aromatase inhibitors over tamoxifen in HER2-positive tumours could also be a chance finding.